Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06143293 · ClinicalTrials.gov registry record · NA

Research Evaluating Vagal Excitation AND Anatomical Links

A NA study of Epilepsy and Depressive Disorder, sponsored by University of Minnesota.

Recruiting
Registry status
NA
Development phase
144
Enrollment target
1
Study location

NCT06143293: Recruiting NA study of Epilepsy and Depressive Disorder, sponsored by University of Minnesota.

NCT06143293 is a NA study of Epilepsy and Depressive Disorder that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 144 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06143293, a NA study of Epilepsy and Depressive Disorder, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
NA
Development phase
144 participants
Enrollment target
1
Study location

Study Summary

The acute and chronic effects of VNS stimulation on various on the autonomic nervous, cardiovascular, immune, and metabolic systems will be compared from noninvasive and minimally invasive physiological recordings and blood draws at various time points throughout the study. These interventions and assessments will be performed in individuals 18 years of age and older who are implanted with a VNS device, which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder. The REVEAL study is not a treatment study; its primary objective is to scientifically investigate the contributing roles of efferent versus afferent vagus nerve modulation of multiple peripheral organs and their dependence on stimulation parameters, in which participants are those who have been implanted with a VNS device be receive standard of care treatment for their epilepsy or depressive disorder.

Primary Outcome

Changes in muscle sympathetic nerve activity burst incidence (bursts/100 heart beats) measured using microneurography of the fibular nerve in response to various vagus nerve stimulation parameters delivered acutely before and after 12 weeks of chronic vagus nerve stimulation.

Conditions Studied

Epilepsy Depressive Disorder

Interventions

  • DEVICE Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2023-12-15
Est. Completion 2026-08-31
Phase NA
University of Minnesota

966 total trials

What NCT06143293 shows while recruiting

NCT06143293 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters is the first listed.

NCT06143293 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06143293 about?

NCT06143293 is a clinical study titled "Research Evaluating Vagal Excitation AND Anatomical Links". The acute and chronic effects of VNS stimulation on various on the autonomic nervous, cardiovascular, immune, and metabolic systems will be compared from noninvasive and minimally invasive physiological recordings and blood draws at various time points throughout the study. These interventions and a...

What is the current status of trial NCT06143293?

This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2023-12-15. Estimated completion is 2026-08-31.

What conditions does trial NCT06143293 study?

This clinical trial studies the following conditions: Epilepsy, Depressive Disorder.

What interventions are being tested in trial NCT06143293?

The interventions under investigation include: Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters (DEVICE).

Who is sponsoring clinical trial NCT06143293?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06143293 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06143293's enrollment target sits among peer trials

144 42nd of 160 higher than 119 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06143293

Source: ClinicalTrials.gov NCT06143293, the US trial registry maintained by the National Library of Medicine. NCT06143293 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.